Introduction
============

Glioma is a common type of primary brain tumor, making up \~30% of all brain and central nervous system tumors and 80% of all malignant brain tumors ([@b1-ol-0-0-7483],[@b2-ol-0-0-7483]). Therapy for the treatment of gliomas consists of tumor resection, followed by radiotherapy and chemotherapy that usually involves O^6^-alkylating agents ([@b3-ol-0-0-7483]--[@b5-ol-0-0-7483]). Despite improvements in the standard of care, the median overall survival (OS) time for patients with glioblastoma multiforme (GBM) has only marginally improved over the past decade, and remains approximately one year ([@b3-ol-0-0-7483],[@b4-ol-0-0-7483]). Thus, therapeutic approaches to cure this malignancy are urgently required to advance treatment.

Temozolomide (TMZ), an alkylating agent with simple oral administration, is used in combination with and following radiotherapy ([@b5-ol-0-0-7483],[@b6-ol-0-0-7483]). Due to the overexpression of phosphorylated protein kinase B (p-AKT), an increasing number of TMZ-resistant cases have been reported clinically ([@b7-ol-0-0-7483]). AKT is a major downstream target of growth factor receptor tyrosine kinases that signal via phosphoinositide 3-kinase (PI3K) ([@b8-ol-0-0-7483],[@b9-ol-0-0-7483]). Activation of AKT has been demonstrated to be associated with increased tumorigenicity and invasiveness ([@b10-ol-0-0-7483]). Inhibitors of the PI3K/AKT signaling pathway, including NVP-BEZ235 and GDC-0941, have been identified to enhance the cytotoxicity of TMZ ([@b7-ol-0-0-7483],[@b11-ol-0-0-7483],[@b12-ol-0-0-7483]).

The excessive growth and metastasis of malignant gliomas may be controlled by a recombinant chlorotoxin-like toxin in the venom of the scorpion *Buthus martensii* Kirsch (*Bm*K CT) fusion protein ([@b13-ol-0-0-7483]). Similarly, the significance of *Bm*K CT had been well documented as a novel blocker of chloride channels and matrix metallopeptidase 2 ([@b14-ol-0-0-7483],[@b15-ol-0-0-7483]). Based on the aforementioned preclinical studies, the combination of *Bm*K CT and TMZ may be an effective treatment for patients with GBM. Therefore, *Bm*K CT combined with TMZ in glioma treatment was deemed to be worthy of further study.

In the present study, the antitumor effect of glutathione S-transferase (GST)-*Bm*K CT combined with TMZ was investigated using the human malignant glioma U251 cell line. The molecular mechanisms underlying this synergistic effect were also investigated.

Materials and methods
=====================

### Materials and protein preparation

The gene sequence of *Bm*K CT was amplified by polymerase chain reaction (PCR) from the vector pRSETc-*Bm*K CT (constructed in Molecular Biology Laboratory, Institute of Biotechnology, Shanxi University, Taiyuan, China) and cloned into pGEX-6p-1 (GE Healthcare Life Sciences, Shanghai, China) to construct the expression vector. The forward primer was 5′-CGCGGATCCATGTGCGGTCCGTGCTTC-3′ (*Bam*HI enzyme site), and the reverse primer was 5′-CCGCTCGAGTCAGATACGGTTGCACAG-3′ (*Xho*I enzyme site). PCR was performed using Taq DNA polymerase (cat no. RR001A; Takara Biotechnology Co., Ltd., Dalian, China) and the thermocycling conditions were as follows: 95°C for 5 min, 40 cycles at 95°C for 30 sec, 63°C for 30 sec and 72°C for 30 sec, followed by 72°C for 5 min. The product of the PCR was fused with the GST gene under the regulation of the tac promoter (Ptac). The expression of Ptac was proportional to the concentration of isopropyl β-D-1-thiogalactopyranoside (IPTG). The recombinant plasmid pGEX-6p-1-*Bm*K CT was transformed into *E. coli* BL21 (DE3). The recombinant GST-*Bm*K CT fusion protein was induced using 0.4 mM IPTG at 37°C for 4 h and purified using a GSH affinity chromatography column (GE Healthcare Life Sciences) according to manufacturer\'s protocols. Minipreparation of GST protein was performed and the protein was purified using a GSH affinity chromatography column via the transformation of empty plasmid pGEX-6p-1 into *E. coli* BL21 (DE3), and was then used as a control sample in the present study. The expression and purification of GST and GST-*Bm*K CT proteins were analyzed using 10% SDS-PAGE gel. The U251 human GBM cell line was kindly provided by Dr Tao Hu (Department of Neurosurgery, Shanxi Provincial People\'s Hospital, Taiyuan, China).

### Cell culture

Cell cultures were prepared and maintained according to standard cell culture procedures. The human glioma cell line U251 was cultured in complete medium, consisting of Dulbecco\'s modified Eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing high glucose and pyruvate, supplemented with 10% fetal bovine serum (FBS Premium; PAN-Biotech GmbH, Aidenbach, Germany), 2 mM glutamine, 100 U ml^−1^ penicillin G and 100 ng ml^−1^ streptomycin. Cells were maintained at 37°C in a humidified 5% CO~2~ atmosphere. The cells were dissociated using TE (0.25% trypsin and 0.02% EDTA solution; Gibco; Thermo Fisher Scientific, Inc.). For the apoptotic experiments, cells were dissociated using 0.25% Trypsin and EDTA free solution (Gibco; Thermo Fisher Scientific, Inc.).

### Drug treatment

Cells were harvested and 5×10^4^ cells were plated in each well of 12-well plate and after 24 h later, cells were treated with 1.12 µM GST, 1.12 µM GST-*Bm*K CT and 0.1 mM TMZ (Merck & Co., Inc., Whitehouse Station, NJ, USA). *Bm*K CT was a homolog of chlorotoxin (CTX). CTX could inhibit U251 cell transwell migration at the inhibition rate of 56.26% under 1 µM ([@b16-ol-0-0-7483]). Based on the aforementioned study, the concentration of *Bm*K CT used in the present study was set at 1.12 µM. The half maximal inhibitory concentration (IC~50~) value of TMZ, defined as the concentration that reduces the global growth of cells by 50%, was previously determined to be \~0.2 mM ([@b17-ol-0-0-7483]). Therefore, the concentration of TMZ used in the present study was set at 0.1 mM, which was the same as published data of TMZ used for glioma cells ([@b17-ol-0-0-7483],[@b18-ol-0-0-7483]). TMZ stocks were prepared by dissolving the drug in dimethyl sulfoxide and stored at 4°C. Following treatment, cells were gently washed with phosphate buffer saline (PBS), incubated in fresh media at 37°C, and harvested at various time periods.

### Cell viability assay

Cell viability was assessed using the MTT method. A total of 1×10^3^ cells were seeded into each well of a 96-well culture plate. In brief, U251 cells were treated with GST, GST-*Bm*K CT and TMZ, and incubated for 1, 2, 3, 4 and 5 days. The liquid was discarded and 100 µl sanlian dissolved liquid (10% SDS, 5% isobutyl alcohol, 0.01 M HCl) was added to dissolve the purple formazan. The absorbance at 570 nm was measured using a microplate reader following incubation. Subsequently, a calibration curve was prepared using the data obtained from the wells that contained known numbers of viable cells. The experiment was performed in six replicates and repeated three times.

### Cell cycle assay

U251 cells were plated at a density of 5×10^4^ cells per well in 12-well plates. After 96 h of treatment with GST or GST-BmK CT in the presence or absence of TMZ, cells were harvested and fixed in 70% ethanol at −20°C overnight. Subsequently, the cells were washed and resuspended in 100 µl PBS containing 5 µg/ml propidium iodide (PI; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 100 µg/ml RNase A (Fermentas; Thermo Fisher Scientific, Inc.) for 1 h at room temperature in the dark. Each group of 2×10^4^ cells were subsequently analyzed using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA); data were analyzed using FlowJo software (version 7.6; FlowJo LLC, Ashland, OR, USA). Cell cycle status was determined by measuring the cellular DNA content, following staining with PI.

### Apoptosis assay

A total of 5×10^4^ U251 cells were plated onto 12-well plates and treated with GST-*Bm*K CT (1.12 µM), TMZ (100 µM), and the combination of the two, respectively. The apoptosis ratio was analyzed 96 h post-treatment using a StarGlow Annexin V-fluorescein isothiocyanate (FITC)/PI Apoptosis Detection kit (cat no. c203-05; GenStar BioSolutions Co., Ltd., Beijing, China). Annexin V-FITC and PI double staining was performed at room temperature for 5 min and was used to evaluate the percentage of apoptotic cells. Annexin V^−^ and PI^−^ cells were used as the controls. Annexin V^+^ and PI^−^ cells were designated as those in early-stage apoptosis, Annexin V^−^ and PI^+^ cells were designated as necrotic, and Annexin V^+^ and PI^+^ cells as late-stage apoptosis. The stained cells were quantified using a FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo software. Tests were replicated in triplicate, and repeated three times.

### RNA isolation and reverse transcription-quantitative (RT-q) PCR

Total mRNA was isolated from tumor cells using TRIzol™ Reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. cDNA was synthesized using the PrimeScript^®^ First Strand cDNA Synthesis kit (cat no. D6110A; Takara Biotechnology Co., Ltd., Dalian, China). The transcription conditions were as follows: 37°C for 15 min, 85°C for 5 sec and 4°C for 5 min. qPCR was performed using the CFX96 Real-Time PCR Detection System (cat no. 185-5195; Bio-Rad Laboratories, Inc., Hercules, CA, USA) with the SYBR^®^ PrimeScript™ RT-PCR kit (cat no. DDR083A; Takara Biotechnology Co., Ltd.). The thermocycling conditions were as follows: 95°C for 5 min, followed by 40 cycles at 95°C for 5 sec and 60°C for 30 sec. The 2^−ΔΔCq^ method was used to quantify gene expression ([@b19-ol-0-0-7483]). Transcript levels were normalized to those of GAPDH. The primers sequences for RT-qPCR were as follows: PTEN forward, 5′-CCTTCTCCATCTCCTGTGTAATCAA-3′ and reverse, 5′-GTTGACTGATGTAGGTACTAACAGCAT-3′; and GAPDH forward, 5′-AACGGGAAGCTTGTCATCAATGGAAA-3′ and reverse, 5′-GCATCAGCAGAGGGGGCAGAG-3′.

### Western blot analysis

U251 cells were treated with GST, GST-*Bm*K CT or TMZ for 1, 2, 4, 8 and 16 h. Subsequently, the cultured cells were washed twice in PBS after treatment at the indicated time points (0, 1, 2, 4, 8 and 16 h) prior to lysis using the M-PER^®^ Mammalian Protein Extraction Reagent (cat no. 75801; Thermo Fisher Scientific, Inc.) supplemented with a proteinase inhibitor cocktail (cat no. 04693116001; Roche Diagnostics GmbH, Mannheim, Germany), phosphatase inhibitor cocktail (cat no. 04906845001; Roche Diagnostics GmbH) and phenylmethylsulfonyl for 30 min on ice. The concentration of protein was quantitated using a BSA kit (cat no. QJ223202; Thermo Fisher Scientific, Inc.). An equal amount (20 µg/lane) of protein lysates was resolved to 10% SDS-PAGE gel. Proteins were transferred onto polyvinylidene difluoride membranes with a 0.45 µm pore size (EMD Millipore, Billerica, MA, USA), which were then blocked with 5% bovine serum albumin at room temperature for 1 h and probed with primary antibodies at 4°C overnight. The following primary antibodies, all of which were diluted at 1:1,000, were used in the present study: Anti-GST (cat no. D110271; Sangon Biotech), anti-β-actin (cat no. LK9001L; Tianjin SunGene Biotech Co., Ltd., Tianjin, China), anti-AKT (cat no. 2920S; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-p-AKT (cat no. 4060S; Cell Signaling Technology, Inc.), anti-B cell lymphoma 2 (Bcl-2; cat no. 3498S; Cell Signaling Technology, Inc.), anti-Bcl-2 associated X protein (Bax; cat no. 2772S; Cell Signaling Technology, Inc.), anti-caspase-9 (cat no. ab202068; Abcam, Cambridge, UK) and anti-caspase-3 (cat no. 9664S; Cell Signaling Technology, Inc.). They were subsequently incubated with a secondary horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (cat no. 31210; dilution, 1:5,000) or a goat anti-mouse IgG antibody (cat no. 31431; dilution, 1:5,000; both Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Results were visualized using the SuperSignal West Dura chemiluminescent substrate (cat no. QJ220977; Thermo Fisher Scientific, Inc.). ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to quantify the band density.

### Statistical analysis

Data are presented as the mean ± standard deviation. Experiments were repeated three or six times. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Two-way analysis of variance, followed by a Bonferroni\'s post hoc test, and the Student\'s t-test were applied to calculate the statistical difference as appropriate. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Construction and purification of recombinant GST-BmK CT

The gene *Bm*K CT was fused with GST via the *Bam*HI and *Xho*I sites under the regulation of Ptac ([Fig. 1A](#f1-ol-0-0-7483){ref-type="fig"}). The pGEX-6p-1-*Bm*K CT was transfected into *E. coli* BL21 (DE3). Then the recombinant protein GST-*Bm*K CT was expressed via induction with IPTG. The recombinant protein was collected and concentrated into PBS. A BCA kit was used to determine the concentration of protein. The GST-*Bm*K CT protein concentration was 6.62 mg/ml (224 µM). GST was produced via the same strategy and the concentration was adjusted to 224 µM. The proteins were diluted to 1.12 µM in complete medium. The expressed proteins of BL21 (DE3)/pGEX-6P-1 or BL21(DE3)/pGEX-6P-1-*Bm*K CT, the proteins bound to glutathione sepharose beads, and purified GST or GST-*Bm*K CT were analyzed using 10% SDS-PAGE gel ([Fig. 1B](#f1-ol-0-0-7483){ref-type="fig"}) and immunologically identified using western blot analysis ([Fig. 1C](#f1-ol-0-0-7483){ref-type="fig"}).

### GST-BmK CT increases the inhibitive effect of TMZ on U251 cell viability

The number of GST and GST-*Bm*K CT-treated cells following TMZ administration were detected using an MTT assay at 1, 2, 3, 4 and 5 days post treatment. In this assay, GST protein demonstrated no effect on the proliferation of U251 cells, as compared with the control group. However, GST-*Bm*K CT protein and TMZ inhibited the growth of U251 cells in a time-dependent manner, compared with the control group (P\<0.001). Furthermore, there was an increased inhibitory effect when GST-*Bm*K CT was combined with TMZ compared with the effects of individual treatments (P\<0.001) ([Fig. 2A-F](#f2-ol-0-0-7483){ref-type="fig"}). The MTT assay revealed that TMZ treatment decreased cell viability to 36±1.8% of the control. When TMZ was combined with *Bm*K CT, cell viability was further inhibited to 22±2.0% of the control after 5 days ([Fig. 2F](#f2-ol-0-0-7483){ref-type="fig"}). These results demonstrated that TMZ combined with *Bm*K CT inhibited the viability of U251 cells by an increased degree ([Fig. 2](#f2-ol-0-0-7483){ref-type="fig"}), compared with TMZ single treatment, decreasing the IC~50~ value from a previously reported 0.2 mM ([@b17-ol-0-0-7483]) to 0.1 mM. This suggested that GST-*Bm*K CT protein and TMZ synergistically ([@b20-ol-0-0-7483]) inhibit U251 glioma cell growth.

### GST-BmK CT enhances TMZ-induced cell cycle arrest in U251 cells

To study the anti-proliferative mechanism of *Bm*K CT combined with TMZ, the effect of this combination treatment on the glioma cell cycle was investigated. U251 cells were cultured with 1.12 µM GST or GST-*Bm*K CT in the presence or absence of 100 µM TMZ for 96 h, following which the cell cycle status was analyzed using flow cytometry. As presented in [Fig. 3](#f3-ol-0-0-7483){ref-type="fig"}, *Bm*K CT treatment resulted in cell cycle arrest in the S phase, an effect which did not occur in the control and GST treatment groups. Treatment with TMZ induced G~2~/M phase arrest. Notably, markedly prolonged S and G~2~/M phase arrest durations were observed when *Bm*K CT and TMZ were used in combination ([Fig. 3](#f3-ol-0-0-7483){ref-type="fig"}).

### GST-BmK CT improves TMZ-induced U251 cell apoptosis

To assess the pro-apoptotic effect of *Bm*K CT combined with TMZ, U251 cells were treated with *Bm*K CT in the presence or absence of TMZ. Apoptotic cells were measured using an Annexin-V/PI staining assay. As presented in [Fig. 4A](#f4-ol-0-0-7483){ref-type="fig"}, U251 cells treated with GST-*Bm*K CT protein or TMZ exhibited an increased rate of apoptosis, compared with the control. In particular, there was a significant increase in the number of apoptotic cells in the combined GST-*Bm*K CT and TMZ treatment group ([Fig. 4B](#f4-ol-0-0-7483){ref-type="fig"}). By analyzing the proportions of early- and late-apoptotic cells, GST-*Bm*K CT protein combined with TMZ were identified to have an increased effect on the number of early-apoptotic cells compared with TMZ alone, which was increased by \~2.5-fold ([Fig. 4C and D](#f4-ol-0-0-7483){ref-type="fig"}).

### GST-BmK CT protein induces U251 cell apoptosis by downregulating p-AKT

AKT phosphorylation triggers resistance to TMZ and upregulates the expression of various anti-apoptosis-associated proteins ([@b7-ol-0-0-7483]). To understand the mechanisms underlying the apoptosis induced by the combined treatment, the levels of AKT phosphorylation and apoptosis-associated proteins were investigated using western blot analysis. The results demonstrated that in GST-*Bm*K CT treated U251 cells for 16 h, the phosphorylation of AKT was significantly decreased compared with the control (0 h; [Fig. 5A](#f5-ol-0-0-7483){ref-type="fig"}; P\<0.005), while the phosphorylation of AKT in GST-treated or TMZ-treated U251 cells did not change ([Fig. 5B and C](#f5-ol-0-0-7483){ref-type="fig"}). In addition, the levels of Bax ([Fig. 5D](#f5-ol-0-0-7483){ref-type="fig"}), cleaved caspase-3 and cleaved caspase-9 ([Fig. 5E](#f5-ol-0-0-7483){ref-type="fig"}) were increased in GST-*Bm*K CT treated U251 cells compared with the control (0 h). The expression level of Bcl-2 was revealed to be decreased in the *Bm*K CT treatment group ([Fig. 5D](#f5-ol-0-0-7483){ref-type="fig"}). Furthermore, GST-*Bm*K CT increased the transcription of phosphatase and tensin homolog (PTEN), which is a major negative regulator of the AKT signaling pathway ([@b21-ol-0-0-7483]) ([Fig. 5F](#f5-ol-0-0-7483){ref-type="fig"}); however TMZ did not perform the same function ([Fig. 5G](#f5-ol-0-0-7483){ref-type="fig"}).

### GST-BmK CT synergistically enhances the apoptosis-inducing effects of TMZ in U251 cells via the downregulation of p-AKT

To investigate the contribution of *Bm*K CT to the effects of TMZ, parallel studies were performed, in which U251 cells were treated with *Bm*K CT and TMZ for different lengths of time. As presented in [Fig. 6A](#f6-ol-0-0-7483){ref-type="fig"}, the transcription PTEN was increased compared with the control (0 h) when the cells were stimulated by GST-*Bm*K CT protein combined with TMZ. The results revealed that this drug combination may enhance the suppressive effect on AKT phosphorylation ([Fig. 6B](#f6-ol-0-0-7483){ref-type="fig"}) and the upregulation of pro-apoptotic proteins in U251 cells ([Fig. 6C](#f6-ol-0-0-7483){ref-type="fig"}), compared with the control (0 h). Taken together, these results suggest that *Bm*K CT enhances the apoptosis sensitivity of TMZ-treated U251 glioma cells by downregulating p-AKT.

Discussion
==========

Accumulating evidence has demonstrated that GBM is resistant to TMZ ([@b7-ol-0-0-7483],[@b11-ol-0-0-7483],[@b12-ol-0-0-7483],[@b22-ol-0-0-7483],[@b23-ol-0-0-7483]). A possible reason for this is that GBM may affect AKT activity and protect against drug-induced cytotoxicity ([@b22-ol-0-0-7483],[@b23-ol-0-0-7483]). In addition, clinical evidence has identified that primary or acquired resistance to TMZ is a major therapeutic problem ([@b11-ol-0-0-7483]). Therefore, a combination therapy that enhances the efficacy of TMZ is required.

*Bm*K CT is a short chain peptide consisting of 35 amino acid residues with four disulfide bridges, and specifically targets glioma cells and inhibits glioma cell growth without any notable toxicity to normal astrocytes ([@b13-ol-0-0-7483]). In the present study, the synergistic effect and mechanism of *Bm*K CT involved in enhancing cell sensitivity to TMZ-induced apoptosis was investigated using malignant glioma U251 cells. The absence of structural characterization of recombinant GST-BmK CT, which contains a 36-mer peptide, is a limitation of the present study.

The results of the present study demonstrated that *Bm*K CT enhances the sensitivity of malignant glioma U251 cells to TMZ-induced apoptosis via the AKT signaling pathway; inhibiting the growth, invasion and migration of glioma cells. It was identified that *Bm*K CT alone induced S phase arrest; however, when combined with TMZ, the treatment significantly induced G~2~/M arrest and cell death. These data revealed that *Bm*K CT arrested the cell cycle at the G~2~/M phase following TMZ-induced DNA damage, in addition to blocking effects at the S/G~2~ transition. Although it is a protein oligopeptide that has been extensively studied, whether it may be an agent with improved ability to cause glioma cell apoptosis when combined with TMZ requires further study. In the present study, the MTT, apoptosis and flow cytometry assays demonstrated that *Bm*K CT combined with TMZ significantly enhanced apoptotic activity and attenuated cell growth.

The results of the present study also demonstrated that the *Bm*K CT protein may inhibit AKT activity and increase U251 glioma cell sensitivity to TMZ. Activation of caspase-9 and caspase-3 was significantly increased in the U251 cells treated with *Bm*K CT for 96 h. In addition, GST-*Bm*K CT was revealed to increase the transcription of PTEN. Although *Bm*K CT was demonstrated to act synergistically with TMZ in inhibiting U251 glioma cell proliferation and generating the highest apoptotic rates, the use of only the U251 cell line is a limitation of the present study. The feasibility of the *Bm*K CT with TMZ combination treatment requires further study in other cell lines.

In conclusion, the results of the present study demonstrated that *Bm*K CT was able to enhance the cytotoxicity of TMZ by downregulating the levels of p-AKT. The results also suggest that *Bm*K CT combined with TMZ is a promising approach for glioma therapy.
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![Construction of pGEX-6P-1-*Bm*K CT and production of recombinant GST-*Bm*K CT. (A) The *Bm*K CT gene was cloned into pGEX-6p-1 to construct the expression vector pGEX-6P-1-*Bm*K CT. (B) SDS-PAGE analysis of the expression and purification of GST and GST-*Bm*K CT. Lane 1--2: The total expressed proteins of BL21(DE3)/pGEX-6P-1 or BL21(DE3)/pGEX-6P-1-*Bm*K CT induced by 0.4 mM IPTG for 4 h; lane 3--4: The proteins after binding to glutathione sepharose beads; lane 5--6: Purified GST or GST-*Bm*K CT extracted by GSH affinity chromatography; lane 7: molecular mass markers. (C) Western blotting was used to identify GST-*Bm*K CT or GST among the total expressed proteins (lane 1), the proteins after binding to glutathione sepharose beads (lane 2), and the purified proteins (lane 3). GST-*Bm*K CT, Glutathione S-transferase fused with *Buthus martensii* Kirsch chlorotoxin-like toxin.](ol-15-02-1537-g00){#f1-ol-0-0-7483}

![Effect of GST-*Bm*K CT combined with TMZ on the proliferation of U251 cells. (A) MTT analysis was performed at (B) 1, (C) 2, (D) 3, (E) 4 and (F) 5 days after treatment. Data are presented as the mean ± standard deviation of six replicates. \*\*\*P\<0.001. GST-*Bm*K CT, *Buthus martensii* Kirsch; TMZ, temozolomide.](ol-15-02-1537-g01){#f2-ol-0-0-7483}

![Cell cycle arrest in U251 cells treated with GST-*Bm*K CT, TMZ, and the combination treatment. (A) Representative results of the percentage of cells in the G~0~/G~1~, S, or G~2~/M phases among U251 cells exposed to GST, GST-*Bm*K CT, TMZ or their combination for 96 h, as detected by flow cytometry. The total number of cells per group exposed to flow cytometry was 20,000. Histograms indicate the percentage of U251 cells in the (B) G~0~/G~1~, (C) S, and (D) G~2~/M phases in three independent experiments. The data are presented as the average of triplicate results from a representative experiment. Bars represent the standard deviation. \*\*P\<0.005, \*\*\*P\<0.001. GST-*Bm*K CT, Glutathione S-transferase fused with *Buthus martensii* Kirsch chlorotoxin-like toxin; TMZ, temozolomide; PI, propidium iodide.](ol-15-02-1537-g02){#f3-ol-0-0-7483}

![GST-*Bm*K CT combined with TMZ enhanced the apoptosis rate of U251 cells. (A) The number of apoptotic cells was determined via flow cytometry 4 days after treatment. (B) The total, (C) early- and (D) late-apoptotic cell numbers were analyzed. Data are presented as the mean ± standard deviation of three replicates. Apoptosis experiments were repeated ≥3 times. \*P\<0.05, \*\*P\<0.005, \*\*\*P\<0.001. GST-*Bm*K CT, Glutathione S-transferase fused with *Buthus martensii* Kirsch chlorotoxin-like toxin; TMZ, temozolomide; PI, propidium iodide; FITC, fluorescein isothiocyanate.](ol-15-02-1537-g03){#f4-ol-0-0-7483}

![*Bm*K CT induced U251 cell apoptosis through downregulating p-AKT. AKT and p-AKT levels were measured in U251 cells treated with (A) 1.12 µM GST-*Bm*K CT, (B) 1.12 µM GST or (C) 100 µM TMZ for 0, 1, 2, 4, 8 or 16 h, using western blotting and the densitometric quantification of AKT and p-AKT was normalized to β-actin. (D) Western blot analysis of Bcl-2, Bax and (E) caspase-3/9 levels and the quantification was normalized to β-actin in the U251 cells stimulated with GST-*Bm*K CT (1.12 µM) for 0, 12, 24, 48, 72 or 96 h. For caspase-3/−9, the antibody was directed against the active fragment. The relative mRNA expression levels of PTEN were assayed by quantitative polymerase chain reaction following the treatment of U251 cells with (F) 1.12 µM GST-*Bm*K CT or (G) 100 µM TMZ for 0, 1, 2, 4, 8 or 16 h. Data are presented as the mean ± standard deviation of three replicates. \*P\<0.05, \*\*P\<0.005, \*\*\*P\<0.001 vs. untreated cells. GST-*Bm*K CT, Glutathione S-transferase fused with *Buthus martensii* Kirsch chlorotoxin-like toxin; TMZ, temozolomide; Bcl-2, B cell lymphoma 2; Bax, Bcl-2 associated X protein; PTEN, phosphatase and tensin homolog; ns, not significant; AKT, protein kinase B.](ol-15-02-1537-g04){#f5-ol-0-0-7483}

![*Bm*K CT enhanced the TMZ-sensitivity and the apoptotic response of U251 cells by downregulating AKT phosphorylation. (A) The relative mRNA expression levels of PTEN were investigated using quantitative polymerase chain reaction following the combination treatment of U251 cells with 1.12 µM GST-*Bm*K CT and 100 µM TMZ in a time-dependent manner. (B) Western blot analysis was performed to evaluate the levels of p-AKT, AKT and (C) various apoptotic proteins in *Bm*K CT and TMZ combination-treated U251 cells. The bands were quantified respectively. Data are presented as the mean ± standard deviation of three replicates. \*P\<0.05, \*\*P\<0.005, \*\*\*P\<0.001 vs. untreated cells. GST-*Bm*K CT, Glutathione S-transferase fused with *Buthus martensii* Kirsch chlorotoxin-like toxin; TMZ, temozolomide; Bcl-2, B cell lymphoma 2; Bax, Bcl-2 associated X protein; PTEN, phosphatase and tensin homolog; ns, not significant; AKT, protein kinase B.](ol-15-02-1537-g05){#f6-ol-0-0-7483}
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